Caribou Biosciences Potential Non-Hodgkin Lymphoma Cell Therapy Shows 'Durable' Responses

MT Newswires Live06-11

Caribou Biosciences' (CRBU) vispa-cel, an off-the-shelf cell therapy using gene editing technology, showed "durable" long-term responses in patients with relapsed or refractory B cell non-Hodgkin lymphoma during an early-stage clinical trial, the company said Thursday.

Among the 27 patients that received a single dose of 80 million genetically edited cells, 82% showed overall response and 67% showed complete response, with a median progression-free survival of 17.1 months, the company said.

Vispa-cel showed a generally well-tolerated safety profile, the company said.

The company plans to enroll 250 patients in a late-stage clinical trial to be conducted at around 75 clinical trial sites worldwide, it said.

Shares of the company were up more than 4% in recent Thursday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment